Chemotherapy News and Research

Latest Chemotherapy News and Research

Engineering chemotherapy drugs' shape increases their ability to target and inhibit cancer cells

Bioengineering researchers at University of California, Santa Barbara have found that changing the shape of chemotherapy drug nanoparticles from spherical to rod-shaped made them up to 10,000 times more effective at specifically targeting and delivering anti-cancer drugs to breast cancer cells.

28 Feb 2013

EpiCept fourth quarter revenue decreases to $0.1 million

EpiCept Corporation today announced operating and financial results for the fourth quarter and full year ended December 31, 2012, and provided an update on the Company's merger with Immune Pharmaceuticals, Ltd. (Immune).

28 Feb 2013

Herceptin may have greater role in treating HER2-negative breast cancer

New research from the University of Michigan Comprehensive Cancer Center finds that the protein HER2 plays a role even in breast cancers that would traditionally be categorized as HER2-negative - and that the drug Herceptin, which targets HER2, may have an even greater role for treating breast cancer and preventing its spread.

28 Feb 2013

Freie Universität Berlin research team examines thermoresponsive nanogels for treatment of cancer

The German Federal Ministry of Education and Research is supporting a new research group at Freie Universität Berlin that is investigating so-called thermoresponsive nanogels.

27 Feb 2013

Taiho Pharmaceutical seeks Japanese approval for TAS-102 to treat colorectal cancer

Taiho Pharmaceutical Co., Ltd. announced on February 27 that it submitted an application on February 26 for approval of the manufacture and marketing of the novel oral nucleoside antitumor agent TAS-102 (combination of trifluorothymidine (FTD) and tipiracil hydrochloride (TPI)) to the Japanese Ministry of Health, Labor and Welfare.

27 Feb 2013

Genetic variation in CD33 influences how AML patients' leukemic cell responds to GO

Researchers from the College of Pharmacy and Medical School working within the Masonic Cancer Center, University of Minnesota, have partnered to identify genetic variations that may help signal which acute myeloid leukemia (AML) patients will benefit or not benefit from one of the newest antileukemic agents.

26 Feb 2013

Trends in patient worry and risk-reducing behaviors in women undergoing breast cancer treatment

Women who have had the lymph nodes under their arm surgically removed during breast cancer treatment are warned to avoid certain practices that can cause lymphedema-a condition that causes chronic, painless swelling in the arm.

26 Feb 2013

Radial forearm free flap shows worth in mandibular reconstruction

The osteocutaneous radial forearm free flap should be used for mandibular reconstruction because of the low rate of long-term donor and recipient site complications, particularly with prophylactic plating of the donor radius, say US scientists.

26 Feb 2013

Complementary medicine risks: an interview with Dr Andrew Boyden, NPS MedicineWise

Complementary medicines include products containing herbs, vitamins, minerals, nutritional supplements, homoeopathic medicines, certain aromatherapy products and traditional Chinese medicines. For this reason they are also called herbal, natural or alternative medicines.

26 Feb 2013

Research roundup: Patients hesitant to focus on costs; Increase in primary care demand is uneven

One way to contain health care spending is to get patients involved in weighing costs of treatment options with their doctors. Researchers recruited 211 medically insured participants to assess their willingness to consider costs when choosing treatments. The authors found that participants generally "preferred better care, even when the relative benefit it offered was marginal, and even when told that the second-best choice still met the threshold of 'good enough' care from a clinician's perspective.

26 Feb 2013

Early lymphoid progenitors thrive in an osteoblastic niche: Study

The Children's Medical Center Research Institute at UT Southwestern has deepened the understanding of the environment within bone marrow that nurtures stem cells, this time identifying the biological setting for specialized blood-forming cells that produce the infection-fighting white blood cells known as T cells and B cells.

25 Feb 2013

Distinct bone marrow niches can nurture different types of blood stem cells

In research that could one day improve the success of stem cell transplants and chemotherapy, scientists have found that distinct niches exist in bone marrow to nurture different types of blood stem cells.

25 Feb 2013

Novel anti-cancer drug conjugates to be evaluated by Ablynx and Spirogen

Ablynx [Euronext Brussels: ABLX] and Spirogen Ltd. announce a research collaboration to evaluate the potential of a novel anti-cancer drug conjugate combining Spirogen's proprietary cytotoxic drugs, pyrrolobenzodiazepines (PBD), and associated linker technology, with Nanobodies® generated using Ablynx’s proprietary technology platform.

25 Feb 2013

Researchers identify new pseudogene that regulates tumour-suppressing PTEN

Researchers at Karolinska Institutet in Sweden have identified a new so-called pseudogene that regulates the tumour-suppressing PTEN gene. They hope that this pseudogene will be able to control PTEN to reverse the tumour process, make the cancer tumour more sensitive to chemotherapy and to prevent the development of resistance.

25 Feb 2013

New, effective and less toxic therapeutic option for patients with HER2-positive breast cancer

Patients with HER2-positive breast cancer, a particularly aggressive form of breast cancer, now have a new, effective and less toxic therapeutic option.

24 Feb 2013

Genentech receives FDA approval for Kadcyla to treat HER2-positive metastatic breast cancer

The U.S. Food and Drug Administration today approved Kadcyla (ado-trastuzumab emtansine), a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer.

23 Feb 2013

New research offers clues for chemotherapy-induced cognitive impairment

It's not unusual for cancer patients being treated with chemotherapy to complain about not being able to think clearly, connect thoughts or concentrate on daily tasks. The complaint - often referred to as chemo-brain - is common. The scientific cause, however, has been difficult to pinpoint.

22 Feb 2013

Weekend reading: Why a trip to the ER costs more than a college semester; Searching for the 'stomach share;' Lessons for the U.S. from Rwanda

Routine Care, Unforgettable Bills .... Sean was allowed to see the doctor only after he advanced MD Anderson $7,500 from his credit card. ... The total cost, in advance, for Sean to get his treatment plan and initial doses of chemotherapy was $83,900.

21 Feb 2013

Article provides examples of how epigenetic drug treatments could be beneficial in treating cancers

A review article by researchers at Boston University School of Medicine (BUSM) proposes a new epigenetic hypothesis linked to tumor production and novel ideas about what causes progenitor cells to develop into cancer cells. Published in the February 2013 issue of Epigenomics, the article provides examples of how epigenetic drug treatments could be beneficial in treating cancers while also decreasing the likelihood of cancer relapse.

21 Feb 2013

‘Liver first’ approach first choice for metastatic rectal cancer

Using the “liver first” approach to treat locally advanced rectal cancer and synchronous liver metastases allows nearly three-quarters of patients to receive optimal neoadjuvant therapy and resection for both their primary tumor and metastases, researchers report.

20 Feb 2013

Chemotherapy News and Research

Latest Chemotherapy News and Research

Engineering chemotherapy drugs' shape increases their ability to target and inhibit cancer cells

EpiCept fourth quarter revenue decreases to $0.1 million

Herceptin may have greater role in treating HER2-negative breast cancer

Freie Universität Berlin research team examines thermoresponsive nanogels for treatment of cancer

Taiho Pharmaceutical seeks Japanese approval for TAS-102 to treat colorectal cancer

Genetic variation in CD33 influences how AML patients' leukemic cell responds to GO

Trends in patient worry and risk-reducing behaviors in women undergoing breast cancer treatment

Radial forearm free flap shows worth in mandibular reconstruction

Complementary medicine risks: an interview with Dr Andrew Boyden, NPS MedicineWise

Research roundup: Patients hesitant to focus on costs; Increase in primary care demand is uneven

Early lymphoid progenitors thrive in an osteoblastic niche: Study

Distinct bone marrow niches can nurture different types of blood stem cells

Novel anti-cancer drug conjugates to be evaluated by Ablynx and Spirogen

Researchers identify new pseudogene that regulates tumour-suppressing PTEN

New, effective and less toxic therapeutic option for patients with HER2-positive breast cancer

Genentech receives FDA approval for Kadcyla to treat HER2-positive metastatic breast cancer

New research offers clues for chemotherapy-induced cognitive impairment

Weekend reading: Why a trip to the ER costs more than a college semester; Searching for the 'stomach share;' Lessons for the U.S. from Rwanda

Article provides examples of how epigenetic drug treatments could be beneficial in treating cancers

‘Liver first’ approach first choice for metastatic rectal cancer

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in